Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

First-line Chemotherapy with Fluorouracil-Epirubicin-Navelbine (FEN) Combination in Advanced Breast Cancer

A. ARDAVANIS, D. TRYFONOPOULOS, G. ORPHANOS, G. IOANNIDIS, M. KARAMOUZIS and G. RIGATOS
Anticancer Research November 2005, 25 (6C) 4493-4498;
A. ARDAVANIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ardavanis{at}yahoo.com
D. TRYFONOPOULOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. ORPHANOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. IOANNIDIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. KARAMOUZIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. RIGATOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 25 no. 6C 4493-4498
PMID 
16334132

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received May 25, 2005
  • Accepted July 22, 2005
  • Published online November 1, 2005.

Copyright & Usage 
Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. A. ARDAVANIS,
  2. D. TRYFONOPOULOS,
  3. G. ORPHANOS,
  4. G. IOANNIDIS,
  5. M. KARAMOUZIS and
  6. G. RIGATOS
  1. First Department of Medical Oncology, St. Savas Anticancer Hospital, Athens, Greece
  1. Correspondence to: Dr A. Ardavanis, 1st Department of Medical Oncology, St. Savas Anticancer Hospital, 171 Alexandras Avenue, 115 22 Athens, Greece. Tel: 6944421525, e-mail: ardavanis{at}yahoo.com

Statistics from Altmetric.com

Cited By...

  • 4 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 25, Issue 6C
1 Nov 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
First-line Chemotherapy with Fluorouracil-Epirubicin-Navelbine (FEN) Combination in Advanced Breast Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 13 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
First-line Chemotherapy with Fluorouracil-Epirubicin-Navelbine (FEN) Combination in Advanced Breast Cancer
A. ARDAVANIS, D. TRYFONOPOULOS, G. ORPHANOS, G. IOANNIDIS, M. KARAMOUZIS, G. RIGATOS
Anticancer Research Nov 2005, 25 (6C) 4493-4498;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
First-line Chemotherapy with Fluorouracil-Epirubicin-Navelbine (FEN) Combination in Advanced Breast Cancer
A. ARDAVANIS, D. TRYFONOPOULOS, G. ORPHANOS, G. IOANNIDIS, M. KARAMOUZIS, G. RIGATOS
Anticancer Research Nov 2005, 25 (6C) 4493-4498;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
  • Google Scholar

More in this TOC Section

  • Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort
  • Unfavorable Outcomes of T3N0 Remnant Gastric Cancer After Distal Gastrectomy
  • Circulating Tumor DNA Methylation Level Is a More Accurate Prognostic Biomarker in Colon Cancer
Show more Clinical Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire